Guardant Health demonstrated strong revenue growth and operational achievements in its oncology and Shield testing businesses. Strategic partnerships and improved gross margins further strengthen the company's position. However, increased operating expenses and uncertainties in future reimbursement and guideline inclusion present challenges.

Company Guidance

In the recent earnings call for Guardant Health's Q3 2025, the company reported robust performance, with total revenue growing 39% year-over-year to $265.2 million. This growth was driven by a 40% increase in oncology volumes, reaching approximately 74,000 tests, and a 31% rise in oncology revenue to $184.4 million. The biopharma and data segment also performed well, increasing revenue by 18% to $54.7 million, bolstered by two companion diagnostic approvals. Shield, Guardant's screening product, generated $24.1 million in revenue from 24,000 tests, with a strong annual run rate of $100 million in its first year post-FDA approval. The company's non-GAAP gross margin improved to 66%, reflecting cost reductions and enhanced operational efficiencies. Guardant Health also raised its full-year 2025 revenue guidance to a range of $965 million to $970 million, citing strong ongoing demand and strategic initiatives, including new partnerships.

Record Revenue Growth

Guardant Health reported a 39% year-over-year revenue growth, reaching $265 million in Q3 2025 and crossing over $1 billion in annualized revenue for the first time.

Oncology Volume Acceleration

Oncology volumes increased 40% year over year to approximately 74,000 tests, with Guardant360 Liquid delivering its fifth consecutive quarter of accelerating growth.

Biopharma and Data Business Growth

Biopharma and data business revenue increased 18% year over year, with two additional companion diagnostic approvals achieved during the quarter.

Shield Testing Revenue Surge

Shield testing revenue reached $24 million in Q3, driven by 24,000 tests and ASPs close to $900, with strong adherence rates.

Gross Margin Improvement

Non-GAAP gross margin increased to 66% in Q3 2025 from 63% in the prior year period, driven by reductions in Reveal COGS and Shield gross margin improvements.

Positive Free Cash Flow

Excluding the screening business, Guardant Health became cash flow positive one quarter ahead of expectations.

Strategic Partnerships

Announced collaborations with Quest Diagnostics and PathGroup to expand Shield access and accelerate commercial infrastructure build-out.

Guardant Health (GH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	-0.78 / -	-0.9	―	―	―
Oct 29, 2025	2025 (Q3)	-0.79 / -0.74	-0.88	15.91% (+0.14)
Jul 30, 2025	2025 (Q2)	-0.74 / -0.80	-0.84	4.76% (+0.04)
Apr 30, 2025	2025 (Q1)	-0.79 / -0.77	-0.94	18.09% (+0.17)
Feb 20, 2025	2024 (Q4)	-0.78 / -0.90	-1.58	43.04% (+0.68)
Nov 06, 2024	2024 (Q3)	-0.73 / -0.88	-0.73	-20.55% (-0.15)
Aug 07, 2024	2024 (Q2)	-0.75 / -0.84	-0.67	-25.37% (-0.17)
May 09, 2024	2024 (Q1)	-0.88 / -0.94	-1.3	27.69% (+0.36)
Feb 22, 2024	2023 (Q4)	-0.86 / -1.58	-1.36	-16.18% (-0.22)
Nov 06, 2023	2023 (Q3)	-0.97 / -0.73	-1.58	53.80% (+0.85)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 29, 2025	$72.27	$92.41	+27.87%
Jul 30, 2025	$45.19	$40.98	-9.32%
Apr 30, 2025	$47.23	$48.87	+3.47%
Feb 20, 2025	$47.40	$42.87	-9.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Guardant Health (GH) report earnings?

Guardant Health (GH) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).

What is Guardant Health (GH) earnings time?

Guardant Health (GH) earnings time is at Feb 19, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GH EPS forecast?

GH EPS forecast for the fiscal quarter 2025 (Q4) is -0.78.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing